112941-34-1

Basic information

• Product Name: Benzenemethanesulfonamide, 2-methyl-
• CAS NO: 112941-34-1
• Molecular Formula: C8H11NO2S
• Molecular Weight: 185.247
• Mol File: 112941-34-1.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: Benzenemethanesulfonamide, 2-methyl-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzenemethanesulfonamide, 2-methyl-(112941-34-1)
• EPA Substance Registry System: Benzenemethanesulfonamide, 2-methyl-(112941-34-1)

Safety Data

• Hazardous Substances Data: 112941-34-1(Hazardous Substances Data)

Usage

Chemical compound

Benzenemethanesulfonamide, 2-methyl-

Primary use

Sulfonamide antimicrobial agent

Class

Sulfonamide antibiotics

Mechanism of action

Works by inhibiting the growth of bacteria causing bacterial infections

Common use

Production of antibacterial medications in the pharmaceutical industry

Effectiveness

Effective in treating a wide range of bacterial infections

Importance

Valuable tool in the fight against infectious diseases

Caution

Use with guidance of healthcare professional to avoid potential side effects or adverse reactions

Upstream product

• 92614-55-6 2-methylphenylmethanesulfonyl chloride 

Relevant articles and documents

Design, synthesis and evaluation of sulfonylurea-containing 4-phenoxyquinolines as highly selective c-Met kinase inhibitors

Deregulation of receptor tyrosine kinase c-Met has been reported in human cancers and is considered as an attractive target for small molecule drug discovery. In this study, a series of 4-phenoxyquinoline derivatives bearing sulfonylurea moiety were designed, synthesized and evaluated for their c-Met kinase inhibition and cytotoxicity against tested four cell lines in vitro. The pharmacological data indicated that most of the tested compounds showed moderate to significant potency as compared with foretinib, with the most promising compound 13x (c-Met kinase IC50 = 1.98 nM) demonstrated relatively good selectivity versus 10 other tyrosine kinases and remarkable cytotoxicities against HT460, MKN-45, HT-29 and MDA-MB-231 with IC50 values of 0.055 μM, 0.064 μM, 0.16 μM and 0.49 μM, respectively. The preliminary structure activity relationships indicated that a sulfonylurea moiety as linker as well as mono-EGWs (such as R1 = 4-F) on the terminal phenyl rings contributed to the antitumor activity.

NOVEL SULFONAMIDE DERIVATIVE

A compound of the formula (1): wherein m, n and p is independently an integer of 0 to 4 with the proviso that 3 a?| m + n a?| 8; X is the formula: NR4, etc.; R1, R3 and R4 are a substituted or unsubstituted aryl group, etc.; R2 is a hydrogen atom, etc.; a, b, c, d, e and f are a hydrogen atom or a substituted or unsubstituted alkyl group, etc.; Y is the formula: -SO2-, etc.; and Z is an oxygen atom, etc.; or a prodrug thereof or a pharmaceutically acceptable salt of the same has an activity of potentiating an expression of a low density lipoprotein receptor and thus is useful as an agent for treating hyperlipidemia or arteriosclerosis.